AbbVie Banks On “Pipeline In A Molecule” Strategy For Imbruvica

 
• By Jessica Merrill

AbbVie CEO Richard Gonzalez defended the roughly $21 billion purchase price it offered to pay for Pharmacyclics, citing bullish long-term sales projections for Imbruvica driven by indication expansion.

More from Clinical Trials

More from R&D